Iterum Therapeutics (ITRM) Receives Buy Rating from HC Wainwright & Co | ITRM Stock News

Author's Avatar
May 08, 2025
Article's Main Image

In a recent announcement on May 8, 2025, Iterum Therapeutics (ITRM, Financial) received a positive rating update from the financial services firm HC Wainwright & Co. The analyst behind this update, Joseph Pantginis, has officially assigned a "Buy" rating to the biotechnology firm, with a newly announced price target of $9.00 USD for Iterum Therapeutics (ITRM).

The current "Buy" rating indicates a strong vote of confidence from the analyst community in Iterum Therapeutics (ITRM, Financial), reflecting favorable sentiment towards the company's future performance in the market. Investors will be keen to see how this updated rating and price target impact the stock's movement in the coming months.

Wall Street Analysts Forecast

1920442989298216960.png

Based on the one-year price targets offered by 2 analysts, the average target price for Iterum Therapeutics PLC (ITRM, Financial) is $5.00 with a high estimate of $5.00 and a low estimate of $5.00. The average target implies an
upside of 442.24%
from the current price of $0.92. More detailed estimate data can be found on the Iterum Therapeutics PLC (ITRM) Forecast page.

Based on the consensus recommendation from 1 brokerage firms, Iterum Therapeutics PLC's (ITRM, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.

Disclosures

I/We may personally own shares in some of the companies mentioned above. However, those positions are not material to either the company or to my/our portfolios.